Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barnaby Nelson

Showing results (201-210 of 311) with videos related to

Pageof 32
Sort By:
Biological Psychiatry Global Open Science|October 6, 2025
Functional Coupling and Longitudinal Outcome Prediction in First-Episode PsychosisIsaac Z Pope, Sidhant Chopra, Alexander Holmes, et al.
Schizophrenia Research|August 14, 2021
Association between tobacco use and symptomatology in individuals at ultra-high risk to develop a psychosis: A longitudinal studyHeleen S van der Heijden, Frederike Schirmbeck, Philip McGuire, et al.
Schizophrenia Research|September 2, 2022
Intelligence trajectories in individuals at ultra-high risk for psychosis: An 8-year longitudinal analysisNicholas Cheng, Ashleigh Lin, Stephen Bowden, et al.
The Australian and New Zealand Journal of Psychiatry|August 12, 2009
Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristicsLisa J Phillips, Barnaby Nelson, Hok Pan Yuen, et al.
Early Intervention in Psychiatry|July 20, 2018
Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participantsBrian O'Donoghue, Shona M Francey, Barnaby Nelson, et al.
JAMA Psychiatry|June 23, 2021
Functional Connectivity in Antipsychotic-Treated and Antipsychotic-Naive Patients With First-Episode Psychosis and Low Risk of Self-harm or Aggression: A Secondary Analysis of a Randomized Clinical TrialSidhant Chopra, Shona M Francey, Brian O'Donoghue, et al.
Schizophrenia Research|February 22, 2018
Clinical trajectories in the ultra-high risk for psychosis populationAndrea Polari, Suzie Lavoie, Hok-Pan Yuen, et al.
Schizophrenia Research. Cognition|March 4, 2021
Cognitive ability and metabolic physical health in first-episode psychosisSarah Whitson, Brian O'Donoghue, Robert Hester, et al.
Brain, Behavior, and Immunity|February 27, 2026
Effects of 6-months of SSRI use on DNA-methylation and gene expression in bloodLauren F Barker, Allan F McRae, Hok Pan Yuen, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 1, 2021
Investigation of structural brain correlates of neurological soft signs in individuals at ultra-high risk for psychosisYa Wang, Esmee E Braam, Cassandra M J Wannan, et al.
Pageof 32

Showing results (201-210 of 311) with videos related to

Sort By:
Pageof 32
Biological Psychiatry Global Open Science|October 6, 2025
Functional Coupling and Longitudinal Outcome Prediction in First-Episode PsychosisIsaac Z Pope, Sidhant Chopra, Alexander Holmes, et al.
Schizophrenia Research|August 14, 2021
Association between tobacco use and symptomatology in individuals at ultra-high risk to develop a psychosis: A longitudinal studyHeleen S van der Heijden, Frederike Schirmbeck, Philip McGuire, et al.
Schizophrenia Research|September 2, 2022
Intelligence trajectories in individuals at ultra-high risk for psychosis: An 8-year longitudinal analysisNicholas Cheng, Ashleigh Lin, Stephen Bowden, et al.
The Australian and New Zealand Journal of Psychiatry|August 12, 2009
Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristicsLisa J Phillips, Barnaby Nelson, Hok Pan Yuen, et al.
Early Intervention in Psychiatry|July 20, 2018
Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participantsBrian O'Donoghue, Shona M Francey, Barnaby Nelson, et al.
JAMA Psychiatry|June 23, 2021
Functional Connectivity in Antipsychotic-Treated and Antipsychotic-Naive Patients With First-Episode Psychosis and Low Risk of Self-harm or Aggression: A Secondary Analysis of a Randomized Clinical TrialSidhant Chopra, Shona M Francey, Brian O'Donoghue, et al.
Schizophrenia Research|February 22, 2018
Clinical trajectories in the ultra-high risk for psychosis populationAndrea Polari, Suzie Lavoie, Hok-Pan Yuen, et al.
Schizophrenia Research. Cognition|March 4, 2021
Cognitive ability and metabolic physical health in first-episode psychosisSarah Whitson, Brian O'Donoghue, Robert Hester, et al.
Brain, Behavior, and Immunity|February 27, 2026
Effects of 6-months of SSRI use on DNA-methylation and gene expression in bloodLauren F Barker, Allan F McRae, Hok Pan Yuen, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 1, 2021
Investigation of structural brain correlates of neurological soft signs in individuals at ultra-high risk for psychosisYa Wang, Esmee E Braam, Cassandra M J Wannan, et al.
Pageof 32